Suzana M.
- Country
- Germany
- Department
- Frauenklinik
Research Overview
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
- Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine or Investigator's Choice Chemotherapy in Patients with FRα-High or FRα-Low Platinum-Resistant Epithelial Ovarian Cancer
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
Data & Insights
Has run more than one trial at 117 of 255 partner sites.
Specializations
Gynaecologic oncology
Suzana Mittelstadt is involved in clinical research focused on endometrial cancer and ovarian cancer, with attention to advanced, recurrent, metastatic, and platinum-resistant disease settings. Her work includes studies in mismatch-repair deficient endometrial cancer, HER2-expressing ovarian cancer, and FRα-defined ovarian cancer subtypes.
- Endometrial cancer
- Advanced ovarian cancer
- Platinum-resistant disease
Her therapeutic interests also extend to biomarker-directed treatment strategies in histologically diverse gynecologic malignancies, including recurrent and molecularly selected populations.
Breast cancer
Her clinical trial activity includes treatment for hormone receptor-positive, HER2-negative breast cancer in locally advanced and metastatic disease. The research landscape reflects interest in endocrine-based treatment approaches and targeted combinations for disease control after progression.
- Hormone receptor-positive breast cancer
- HER2-negative metastatic disease
- Endocrine therapy combinations
This area highlights therapeutic focus on systemic management of advanced breast cancer with emphasis on precision-oriented care.
Hematologic malignancies
Suzana Mittelstadt is also active in trials involving chronic lymphocytic leukemia, follicular lymphoma, Hodgkin lymphoma, multiple myeloma, and Philadelphia chromosome-positive acute lymphoblastic leukemia. These studies span relapsed, refractory, and newly diagnosed settings across several blood cancers.
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Multiple myeloma
Her involvement includes therapies directed at disease control, maintenance treatment, and response optimization in hematologic oncology.
Targeted and immunotherapy-based treatment
Her trial portfolio includes research on BTK inhibition, EZH2-directed therapy, antibody-drug conjugates, bispecific and monoclonal antibodies, and immunomodulatory treatment. These therapeutic domains appear across solid tumors and hematologic cancers, reflecting a strong focus on targeted oncology.
- BTK inhibition
- Antibody-based therapy
- Immunomodulatory treatment
Her clinical research also includes biomarker-linked treatment selection, especially in FRα-, HER2-, EZH2-, and mismatch-repair-defined disease groups.
Colorectal cancer
Another area of involvement is metastatic colorectal cancer, with interest in post-resection and post-ablation systemic treatment strategies. This adds a gastrointestinal oncology component to her broader therapeutic portfolio.
- Metastatic colorectal cancer
- Post-resection treatment
- Post-ablation therapy
Her work in this domain supports clinical evaluation of disease-directed treatment options in the metastatic setting.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.